Table 1. Demographic, anthropometric, biochemical, hemodynamic and dialysis characteristics of the study population.
| Total Cohort | Echo cor cohort | |
| n = 714 | n = 327 | |
| Demographic data | ||
| Male gender | 445 (62%) | 200 (61%) |
| Race, Caucasian | 304 (85%) | 263 (80%) |
| Age, years | 64.1±13.7 | 63.0±13.3 |
| Smoking | 133 (19%) | 66 (20%) |
| Anthropometrics | ||
| Length (cm) | 168±10 | 168±11 |
| Weight (kg) | 72.4±14.4 | 72.1±14.3 |
| BMI (kg/m2) | 25.4±14.4 | 25.5±4.9 |
| Body Surface Area (m2) | 1.85 (0.28)* | 1.85 (0.30)* |
| Dialysis Properties | ||
| Dialysis vintage (years) | 1.8 (1.0–4.0)* | 2.0 (1.0–4.0)* |
| Duration of dialysis (minutes) | 226±23 | 225±23 |
| Blood flow (mL/minute) | 300 (300–348)* | 300 (300–350)* |
| spKt/Vurea | 1.40±0.22 | 1.39±0.20 |
| AV fistula | 279 (78%) | 260 (80%) |
| Patients with residual kidney function | 186 (52%) | 171 (52%) |
| Comorbidities | ||
| Cardiovascular disease | 313 (44%) | 146 (45%) |
| Diabetes | 170 (24%) | 83 (25%) |
| Previous kidney transplant | 78 (11%) | 30 (9%) |
| Laboratory parameters | ||
| Hemoglobin (g/dL) | 11.8±0.40 | 11.8±1.3 |
| Phosphate (mmol/L) | 1.64±0.49 | 1.67±0.50 |
| Calcium (mmol/L) | 2.31±0.18 | 2.30±0.18 |
| Albumin (g/L) | 40.4±3.8 | 41.2 (37.9–43.5)* |
| Creatinine (µmol/L), pre-dialysis | 861±255 | 883±252 |
| hsCRP (mg/L) | - | 4.0 (1.6–11.9)* |
| Il-6 (pg/mL) | - | 2.0 (1.2–3.8)* |
| CTGF (nmol/L) | - | 3.6 (2.8–4.3)* |
| Hepcidin -25 (nM) | - | 14.2 (6.3–22.4)* |
| Ferritin (ng/mL) | - | 377 (211–597)* |
| TSAT (%) | - | 22 (15–29)* |
| Medication | ||
| Erythropietin therapy | 314 (88%) | 295 (91%) |
| Diuretic therapy | 250 (35%) | 129 (39%) |
| Beta-blocker therapy | 184 (51%) | 174 (53%) |
| RAS inhibitor therapy | 179 (50%) | 162 (50%) |
| Lipid lowering therapy | 196 (55%) | 152 (47%) |
| Vitamin D administration | 227 (63%) | 222 (68%) |
| Phosphate binding therapy | 445 (62%) | 194 (59%) |
| Platelet aggregation therapy or coumarines | 111 (34%) | 122 (36%) |
| Iron supplements | 476 (67%) | 213 (65%) |
| Hemodynamic measurements | ||
| Systolic blood pressure (mm Hg) | 147±21 | 142±19 |
| Diastolic blood pressure (mm Hg) | 75±12 | 74±10 |
| LVEDD (mm) | - | 10 (9–11)* |
| LVESD (mm) | - | 32 (27–38)* |
| EFLV (%) | - | 65 (55–72)* |
| LVM (g) | - | 227 (183–279)* |
| LVH | - | 230 (71%) |
*
:median and IQR (P25–P75).
AV: arterio-venous;BMI: mody mass index; CTGF: connective tissue growth factor; EFLV: ejection fraction of left ventricle; hsCRP: high sensitivity C-reactive protein; Il-6: interleukin 6; LVEDD: left ventricular end diastolic diameter; LVESD: left ventricular end systolic diameter; LVH: left ventricular hypertrophy; LVM: left ventricular mass; RAS: renin-angiotensin system; TSAT: transferrin saturation.